Fri, January 8, 2021

Matthew Harrison Downgraded (SRPT) to Hold and Decreased Target to $95 on, Jan 8th, 2021

Matthew Harrison of Morgan Stanley, Downgraded "Sarepta Therapeutics, Inc." (SRPT) to Hold and Decreased Target from $182 to $95 on, Jan 8th, 2021.

Matthew has made no other calls on SRPT in the last 4 months.



There are 2 other peers that have a rating on SRPT. Out of the 2 peers that are also analyzing SRPT, 0 agree with Matthew's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Matthew


  • Colin Bristow of "UBS" Initiated at Strong Buy and Held Target at $212 on, Wednesday, October 28th, 2020
  • Joel Beatty of "Citigroup" Maintained at Strong Buy with Increased Target to $190 on, Tuesday, September 15th, 2020